D-0468-2017 Class III Terminated

Recalled by Dr. Reddy's Laboratories, Inc. — Princeton, NJ

FDA drug recall D-0468-2017 was initiated by Dr. Reddy's Laboratories, Inc. on Oct 13, 2016 and is designated Class III. Reason for recall: Failed impurities/degradation specifications: due to out-of-specification result for the Related Substance Compound C (Impurity 6 - N-Oxide at the 18 month stability station. The recall status is terminated (terminated Jul 24, 2017). Affected quantity: 5,904 bottles.

Recall details

Product Type
Drugs
Report Date
Feb 15, 2017
Initiation Date
Oct 13, 2016
Termination Date
Jul 24, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
5,904 bottles

Product description

Olanzapine tablets, USP, 2.5 mg, packaged in a 30-count bottle, Rx only, Mfd: By: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-163-30

Reason for recall

Failed impurities/degradation specifications: due to out-of-specification result for the Related Substance Compound C (Impurity 6 - N-Oxide at the 18 month stability station.

Distribution pattern

US Nationwide

Code information

C500202

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0468-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0468-2017. Report a data issue: hello@regdatalab.com.